FDA actions in brief
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Abatacept (Orencia, Bristol-Myers Squibb) was approved to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).
FDA approved divalproex extended-release tablets (Depakote ER, Abbott) for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.
Novo Nordisk Terminates Collaboration with Hims & Hers
June 23rd 2025The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
Read More
